stockrow
Monday 9 November 2026
Export AGMB’s income statement to Excel — free account
AgomAb Therapeutics NV
AGMB
7.64
0.67
+9.61%
Follow AGMB
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Gross margin, % | — | — | — | — | — | — | — | — | — | — | — | — | ||||||
| EBT | — | — | — | — | — | — | — | — | (50) | (71) | — | +41.4% | ||||||
| EBT margin, % | — | — | — | — | — | — | — | — | 0.00 | 0.00 | — | 0.0 pt | ||||||
| Net income | — | — | — | — | — | — | — | — | (50) | (71) | (157) | +41.3% | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | — | — | — | — | — | — | — | 0.00 | 0.00 | — | n/m | |||||
| Earnings | — | — | — | — | — | — | — | — | (115.88) | (162.00) | — | +39.8% | ||||||
| Cash flow | — | — | — | — | — | — | — | — | (93.64) | (108.19) | 0.00 | +15.5% | ||||||
| Capex | — | — | — | — | — | — | — | — | (1.35) | (0.01) | — | (99.4%) | ||||||
| Free cash flow | — | — | — | — | — | — | — | — | (94.99) | (108.19) | 0.00 | +13.9% | ||||||
| Book value | — | — | — | — | — | — | — | — | 376.11 | 273.71 | 0.00 | (27.2%) | ||||||
| Shares, m | — | — | — | — | — | — | — | — | 1 | 1 | — | 0.0% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | — | — | |||||
| P/S | — | — | — | — | — | — | — | — | — | — | — | — | ||||||
| P/B | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | — | — | — | — | (51) | (59) | (144) | +15.5% | |||||
| Capex | — | — | — | — | — | — | — | — | (1) | 0 | — | (99.4%) | ||||||
| Free cash flow | — | — | — | — | — | — | — | — | (51) | (59) | (144) | +13.9% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | — | — | — | — | — | — | — | 178 | 116 | 277 | (34.8%) | |||||
| Net debt | — | — | — | — | — | — | — | — | (184) | (131) | (292) | (29.0%) | ||||||
| Shareholders’ equity | — | — | — | — | — | — | — | — | 204 | 148 | 309 | (27.2%) | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | — | — | — | — | — | — | — | 0.00 | (44.15) | — | (44.1) pt | |||||
| ROIC | — | — | — | — | — | — | — | — | (167.73) | (240.67) | 0.00 | (72.9) pt | ||||||
| ROE | — | — | — | — | — | — | — | — | 0.00 | (49.87) | — | (49.9) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | — | — | — | — | — | 62 | 62 | — | 0.0% | |||||
| Revenue/emp, $m | — | — | — | — | — | — | — | — | 0.00 | 0.00 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fundamentals updated 26 Oct 2026
AgomAb Therapeutics NV vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| MPLT MapLight Therapeutics, Inc. | $385.1M | — (loss-making) | — | — | n/m | −31.91% (below 0%: shrinking) | — | 0.00% | Compare |
| AGMB AgomAb Therapeutics NV | $376.0M | — | — | — | — | — | — | — | |
| RZLT Rezolute, Inc. | $375.3M | — (loss-making) | — | — | n/m | +40.23% (above 0%: growing) | 0.00% | 0.00% | Compare |
| CTNM Contineum Therapeutics, Inc. | $373.8M | — (loss-making) | — | — | n/m | +10.04% (above 0%: growing) | 100.00% | 0.00% | Compare |
| SRZN Surrozen, Inc. | $364.4M | — (loss-making) | — (loss-making) | +408.65% (above 0%: growing) | n/m | −21.25% (below 0%: shrinking) | 100.00% | (207.40%) | Compare |
| IRD Opus Genetics, Inc. | $347.8M | — (loss-making) | — (loss-making) | −73.80% (below 0%: shrinking) | n/m | −16.37% (below 0%: shrinking) | 100.00% | (2,182.78%) | Compare |
| AVIR Atea Pharmaceuticals, Inc. | $345.7M | — (loss-making) | — (loss-making) | +295.16% (above 0%: growing) | n/m | +85.53% (above 0%: growing) | 0.00% | 0.00% | Compare |
| OBIO Orchestra BioMed Holdings, Inc. | $341.4M | — (loss-making) | — (loss-making) | −89.47% (below 0%: shrinking) | n/m | −25.87% (below 0%: shrinking) | 71.59% | (25,404.55%) | Compare |
| AUTL Autolus Therapeutics PLC Sponsored ADR | $340.7M | — (loss-making) | — (loss-making) | +118.37% (above 0%: growing) | n/m | +67.55% (above 0%: growing) | 55.20% | (95.95%) | Compare |
| Median of peers | $356.1M | — | — | +118.37% | — | −3.17% | 71.59% | (47.97%) |